Compare uniQure N.V. Ordinary Shares (QURE) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Relay Therapeutics Inc. Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Relay Therapeutics Inc. Common Stock trades at $16.91 (market cap $3.81B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 2.6× uniQure N.V. Ordinary Shares's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| QURE | RLAY | |
|---|---|---|
Market Cap | $1.48B | $3.81B |
Volume | 2,488,780 | 1,706,150 |
Sector | Health | Health |
52-Week High | $70.59 | $20.75 |
52-Week Low | $9.03 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $728.62M | $2.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
